Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinomas (RCC) are difficult to diagnose prospectively. We used immunohistochemistry (IHC) to identify fumarate hydratase (FH)-deficient tumors (defined as FH negative, 2-succinocysteine [2SC] positive) in cases diagnosed as "unclassified RCC, high grade or with papillary pattern," or "papillary RCC type 2," from multiple institutions. A total of 124 tumors (from 118 patients) were evaluated by IHC for FH and 2SC. An FH deficiency was found in 24/124 (19%) cases. An indeterminate result (only 1 marker abnormal) was found in 27/124 (22%) cases. In a tissue microarray of 776 RCCs of different types, only 2 (0.5%) tumors, initially considered papillary type 2, were FH deficient. FH mutations were found in 19/21 FH-deficient tumors (with confirmed germline mutations in 9 of 9 tumors in which germline status could be assessed) and in 1/26 FH-indeterminate tumors identified by IHC. No FH mutations were found in 2/21 FH-deficient RCCs, 25/26 FH-indeterminate RCCs, and 10/10 RCCs demonstrating FH expression by IHC. Patients with FH-deficient RCC had a median age of 44 years (range, 21 to 65 y). Average tumor size was 8.2 cm (range, 0.9 to 18 cm). FH-deficient RCCs were characterized by at least focal macronucleoli and demonstrated 2 or more growth patterns in 93% cases. Papillary was the most common (74%) and dominant (59%) pattern, whereas other common patterns included: solid (44%), tubulocystic (41%), cribriform (41%), and cystic (33%). At presentation, 57% were stage ≥pT3, 52% had positive nodes, and 19% had distant metastases. After a mean follow-up of 27 months (range, 1 to 114 mo), 39% of patients were dead of disease, and 26% had disease progression. We conclude that FH and 2SC are useful IHC ancillary tools, which allow recognition of FH-deficient RCC.

*Calgary Laboratory Services and University of Calgary Calgary AB Canada §§McGill University Montreal QC Canada †Charles University Pilsen Czech Republic ‡Institute of Pathology Friedrich Alexander University Erlangen Nürnberg Germany ∥University Clinic Bonn Germany §Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH ‡‡University of Michigan Ann Arbor MI ∥∥University of South Carolina School of Medicine Columbia SC ¶University of Florence Florence Italy Pitié Salpêtrière Hospital Paris France **Hopital Cochin APHP Université Paris Descartes Paris France ††Barts Cancer Institute Queen Mary University of London London United Kingdom ¶¶Sullivan Nicolaides Pathology Gold Coast Qld Australia ***Mater Hospital South Brisbane Qld Australia Douglass Hanly Moir Pathology North Ryde NSW Australia †††Cancer Diagnosis and Pathology Group Kolling Institute of Medical Research Royal North Shore Hospital University of Sydney Sydney NSW Australia

References provided by Crossref.org

Morphological diversity in SDH-deficient renal carcinomas: a three-case exploration of variant features and dedifferentiation

New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217

Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer

Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach

Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma

Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma